Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER+ breast cancer

Shenghong Ma; Tracy Tang; Gary Probst; Andrei Konradi; Chunyu Jin; Fulong Li; J. Silvio Gutkind; Xiang-Dong Fu; Kun-Liang Guan

doi:10.1038/s41467-022-28691-0

Nature Communications (Feb 2022)

Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER+ breast cancer

Shenghong Ma,
Tracy Tang,
Gary Probst,
Andrei Konradi,
Chunyu Jin,
Fulong Li,
J. Silvio Gutkind,
Xiang-Dong Fu,
Kun-Liang Guan

Affiliations

Shenghong Ma: Department of Pharmacology and Moores Cancer Center, University of California San Diego
Tracy Tang: Vivace Therapeutics
Gary Probst: Vivace Therapeutics
Andrei Konradi: Vivace Therapeutics
Chunyu Jin: Howard Hughes Medical Institute, Department of Medicine, University of California San Diego
Fulong Li: Department of Pharmacology and Moores Cancer Center, University of California San Diego
J. Silvio Gutkind: Department of Pharmacology and Moores Cancer Center, University of California San Diego
Xiang-Dong Fu: Department of Cellular and Molecular Medicine, University of California San Diego
Kun-Liang Guan: Department of Pharmacology and Moores Cancer Center, University of California San Diego

DOI: https://doi.org/10.1038/s41467-022-28691-0
Journal volume & issue: Vol. 13, no. 1
pp. 1 – 17

Abstract

Read online

Hippo signalling is reported to be required for proper ESR1 expression. Here the authors reveal that the transcriptional repression of ESR1 is via LATS-YAP-TEAD-VGLL3 axis and the epigenetic regulation of ESR1 super enhancer in ER + breast cancer.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal